Important Information for Zenas BioPharma Shareholders from Levi & Korsinsky Law Firm

Zenas BioPharma Shareholders Encouraged to Act Now

In light of recent developments, shareholders of Zenas BioPharma, Inc. are strongly urged to get in touch with the law firm Levi & Korsinsky, LLP prior to June 16, 2025. This urgent advisory comes as a result of a class action securities lawsuit filed on behalf of investors who may have been negatively impacted by alleged securities fraud relating to the company's IPO.

Class Action Overview

The case aims to represent those who purchased or otherwise acquired shares of Zenas BioPharma following the company's registration statement and related prospectus from its initial public offering in September 2024. Allegations include claims that Zenas BioPharma significantly overstated its capabilities to finance future operations through existing cash reserves and anticipated proceeds from the IPO, which led to misleading public statements.

Why This Matters

As a shareholder, if you have experienced losses related to your investment in Zenas BioPharma, this situation may directly affect your financial interests. The lawsuit is a critical step, allowing shareholders the potential to seek redress for their losses. It’s essential to note that participation in the class action does not necessitate serving as a lead plaintiff, allowing more shareholders to potentially benefit from any compensation that might follow.

No Cost Engagement

Levi & Korsinsky emphasizes that any class members could be eligible for financial reparation without incurring upfront costs or fees. The firm assures that there is no obligation to pursue this opportunity. They have a proven track record, having secured substantial settlements for their clients in previous securities litigation.

What to Do Next

If you are affected and wish to be appointed as a lead plaintiff, you must submit your request to the court by the stipulated deadline of June 16, 2025. Investors are encouraged to act quickly to preserve their rights. Shareholders can easily gather more information and express their interest through Levi & Korsinsky's dedicated link. Additionally, investors can reach out directly to Joseph E. Levi, Esq. via email or phone to discuss their situation in detail.

Expertise of Levi & Korsinsky

Levi & Korsinsky has built a considerable reputation over the last two decades for advocating on behalf of shareholders, successfully retrieving hundreds of millions of dollars for aggrieved investors across various high-stakes cases. With a robust team and depth of experience in complex securities litigation, they are well placed to support Zenas BioPharma investors during this challenging time.